Biib stock price

These events were cited as proof of the base business’s “continued resiliency” and highlighted an undervalued pipeline. The firm also mentioned the potential for Biogen Inc. (NASDAQ:BIIB)’s late-stage studies in depression and lupus, as well as the acceleration of sales potential for its Alzheimer’s medication Leqembi through a planned at-home subcutaneous formulation. Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. ( NASDAQ:BIIB - Free Report ). This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]. Should You Invest $1,000 in Biogen Right Now? Before you consider Biogen, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list. While Biogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here Options Trading Made Easy - Download Now Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy. Get This Free Report BIIB stock price surged nearly 2% intraday after reports indicated expanded commercial reach for its multiple sclerosis portfolio. This development strengthens recurring revenue streams critical for valuation support.